CN110035758B - 用于治疗与线粒体功能障碍相关联的疾病的化合物 - Google Patents

用于治疗与线粒体功能障碍相关联的疾病的化合物 Download PDF

Info

Publication number
CN110035758B
CN110035758B CN201780053445.8A CN201780053445A CN110035758B CN 110035758 B CN110035758 B CN 110035758B CN 201780053445 A CN201780053445 A CN 201780053445A CN 110035758 B CN110035758 B CN 110035758B
Authority
CN
China
Prior art keywords
formula
compound
group
disease
mitochondrial dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780053445.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110035758A (zh
Inventor
A.丹钦
A.塞科夫斯卡
P.加尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ama Biopharmaceutical Co
Original Assignee
Ama Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ama Biopharmaceutical Co filed Critical Ama Biopharmaceutical Co
Publication of CN110035758A publication Critical patent/CN110035758A/zh
Application granted granted Critical
Publication of CN110035758B publication Critical patent/CN110035758B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780053445.8A 2016-08-30 2017-08-30 用于治疗与线粒体功能障碍相关联的疾病的化合物 Active CN110035758B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306094.0A EP3290039B1 (en) 2016-08-30 2016-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction
EP16306094.0 2016-08-30
PCT/EP2017/071812 WO2018041919A1 (en) 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction

Publications (2)

Publication Number Publication Date
CN110035758A CN110035758A (zh) 2019-07-19
CN110035758B true CN110035758B (zh) 2023-06-16

Family

ID=56896495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053445.8A Active CN110035758B (zh) 2016-08-30 2017-08-30 用于治疗与线粒体功能障碍相关联的疾病的化合物

Country Status (15)

Country Link
US (2) US10857135B2 (enExample)
EP (2) EP3290039B1 (enExample)
JP (1) JP7065854B2 (enExample)
KR (1) KR20200011927A (enExample)
CN (1) CN110035758B (enExample)
AU (1) AU2017317651B2 (enExample)
BR (1) BR112019004236A2 (enExample)
CA (1) CA3034694A1 (enExample)
ES (1) ES2800917T3 (enExample)
MA (1) MA46099A (enExample)
MX (1) MX394782B (enExample)
RU (1) RU2019108824A (enExample)
SG (1) SG11201901689YA (enExample)
WO (1) WO2018041919A1 (enExample)
ZA (1) ZA201900997B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2800917T3 (es) * 2016-08-30 2021-01-05 Amabiotics Compuestos para tratar enfermedades asociadas con una disfunción mitocondrial
KR20210005848A (ko) * 2018-03-07 2021-01-15 아마바이오틱스 알츠하이머병을 치료하기 위한 화합물
US20220096574A1 (en) * 2019-01-29 2022-03-31 Holobiome, Inc. Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis
EP4028014A1 (en) * 2019-09-12 2022-07-20 Stellate Therapeutics Compounds for treating neurodegenerative diseases
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia
CN116850191A (zh) * 2023-06-16 2023-10-10 山东大学齐鲁医院 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
CN105073089A (zh) * 2013-02-21 2015-11-18 埃玛生物公司 Q碱的美容用途
WO2016050804A1 (en) * 2014-09-29 2016-04-07 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936615A (ja) * 1982-08-24 1984-02-28 Takeda Chem Ind Ltd 発がん予防剤
WO1996033703A2 (en) * 1995-04-25 1996-10-31 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
ES2800917T3 (es) * 2016-08-30 2021-01-05 Amabiotics Compuestos para tratar enfermedades asociadas con una disfunción mitocondrial

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
CN105073089A (zh) * 2013-02-21 2015-11-18 埃玛生物公司 Q碱的美容用途
WO2016050804A1 (en) * 2014-09-29 2016-04-07 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Diagnosis and molecular basis of mitochondrial respiratory chain disorders: Exome sequencing for disease gene identification;Ohtake, A等;《BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS》;20140124;第1840卷(第4期);1355-1359 *
Expanding insights of mitochondrial dysfunction in Parkinson"s disease;Abou-Sleiman, PM等;《NATURE REVIEWS NEUROSCIENCE》;20060301;第7卷(第3期);207-219 *
Mitochondrial dysfunction in cancer;Modica-Napolitano, JS等;《MITOCHONDRION》;20040901;第4卷(第5-6期);755-762 *
Mitochondrial Dysfunction in Neurodegenerative Diseases and Cancer;de Moura, Michelle Barbi等;《ENVIRONMENTAL AND MOLECULAR MUTAGENESIS》;20100413;第51卷(第5期);391-405 *
Modulation in the activity of lactate dehydrogenase and level of c-Myc and c-Fos by modified base queuine in cancer;Pathak, Chandramani等;《CANCER BIOLOGY & THERAPY》;20080131;第7卷(第1期);85-91 *
Queuosine modification of tRNA: its divergent role in cellular machinery;Manjula VINAYAK等;《BIOSCIENCE REPORTS》;20091123;第30卷(第2期);135-148 *
Reisser,T等.THE NUTRIENT FACTOR QUEUINE PROTECTS HELA-CELLS FROM HYPOXIC STRESS AND IMPROVES METABOLIC ADAPTATION TO OXYGEN AVAILABILITY.《EUROPEAN JOURNAL OF BIOCHEMISTRY》.1994,第221卷(第3期),979-986. *
Specific lack of the hypermodified nucleoside, queuosine, in hepatoma mitochondrial aspartate transfer RNA and its possible biological significance;Randerath,E等;《Cancer Research》;19840331;第44卷(第3期);1167-1171 *
THE NUTRIENT FACTOR QUEUINE PROTECTS HELA-CELLS FROM HYPOXIC STRESS AND IMPROVES METABOLIC ADAPTATION TO OXYGEN AVAILABILITY;Reisser,T等;《EUROPEAN JOURNAL OF BIOCHEMISTRY》;19940501;第221卷(第3期);979-986 *

Also Published As

Publication number Publication date
US11684611B2 (en) 2023-06-27
JP2019526634A (ja) 2019-09-19
US20210046056A1 (en) 2021-02-18
EP3290039B1 (en) 2020-03-25
CN110035758A (zh) 2019-07-19
MA46099A (fr) 2019-07-10
BR112019004236A2 (pt) 2019-05-28
ZA201900997B (en) 2020-05-27
US10857135B2 (en) 2020-12-08
MX394782B (es) 2025-03-24
AU2017317651B2 (en) 2022-12-15
WO2018041919A1 (en) 2018-03-08
MX2019002369A (es) 2019-11-07
RU2019108824A (ru) 2020-10-01
US20190224174A1 (en) 2019-07-25
ES2800917T3 (es) 2021-01-05
KR20200011927A (ko) 2020-02-04
EP3290039A1 (en) 2018-03-07
JP7065854B2 (ja) 2022-05-12
SG11201901689YA (en) 2019-03-28
AU2017317651A1 (en) 2019-03-07
CA3034694A1 (en) 2018-03-08
EP3506903A1 (en) 2019-07-10
RU2019108824A3 (enExample) 2020-12-31

Similar Documents

Publication Publication Date Title
CN110035758B (zh) 用于治疗与线粒体功能障碍相关联的疾病的化合物
JP2022033788A (ja) ソベチロム誘導体
ES2575684T3 (es) Agonistas de receptores de neurotrofinas y su uso como medicamentos
Shan et al. Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53
Liu et al. The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson’s disease in mice
CN107001413A (zh) 环肽衍生物及其制造方法和组合物
Xin et al. Protective effects of Cervus nippon Temminck velvet antler polypeptides against MPP+-induced cytotoxicity in SH-SY5Y neuroblastoma cells
Wang et al. The inflammatory injury in the striatal microglia-dopaminergic-neuron crosstalk involved in Tourette syndrome development
US20120083464A1 (en) Neuroprotective properties of 5'-methylthioadenosine
Zhang et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets
Wang et al. The activation of spliced X-box binding protein 1 by isorhynchophylline therapy improves diabetic encephalopathy
Edalatmanesh et al. Valproic acid-mediated inhibition of trimethyltin-induced deficits in memory and learning in the rat does not directly depend on its anti-oxidant properties
KR20040012396A (ko) 뇌신경성장인자 증강작용을 갖는 백강잠 추출물 및 이의활성성분을 함유하는 약학적 제제
CN112236145A (zh) 治疗阿尔茨海默氏病的化合物
Mao et al. Study on the interventional effects of Chlamydomonas reinhardtii peptides on chronic unpredictable mild stress-induced depressive-like model mice through metabolomics and microbiota
US20230040247A1 (en) Compounds for treating neurodegenerative diseases
WO2021048431A1 (en) Compounds for treating ataxia
Zhang The inflammatory injury in the striatal microglia-dopaminergic
Galione et al. Stereospecific rapid activation of Transcription Factor EB (TFEB) by Levacetylleucine (NALL)
Chen et al. GDNF alleviates depression in Parkinson's disease by inhibiting α-synuclein aggregation and facilitating DA transmission from VTA to NAc
PERK et al. TAURINE GRP78 IRE1
Wang Human olfactory epithelial-derived progenitors: A potential source for cell therapy for Parkinson's disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant